STCube Announces Prospects for Technology Export at JP Morgan Healthcare Conference... "Detailed Discussions Planned"

STCube is set to participate in the world's largest investment event in the pharmaceutical and biotech sector, the 'JP Morgan Healthcare Conference' (hereinafter JP Morgan). Starting with JP Morgan, the biggest bio conference at the beginning of the year attended by global big pharma, the company aims to open the door to full-scale technology licensing (L/O) activities.

On the 9th, STCube announced that it will hold business meetings with multiple top global big pharma companies at the JP Morgan conference in January next year to discuss the technology licensing of 'Nelmastovat.' Nelmastovat is STCube's flagship pipeline, a first-in-class BTN1A1-targeting immune checkpoint inhibitor.

An STCube representative said, "We have pre-scheduled multiple business meetings with global big pharma companies that have been continuously discussing Nelmastovat technology collaboration as well as new companies. This is the first offline meeting held at the request of the other party following data exchange on Nelmastovat’s Phase 1b/2 clinical trials, so we are carefully preparing for the conference."

They added, "We are confident that the optimal market environment for successful technology licensing has been established based on scientific validation of Nelmastovat, benefits to cancer patients, market competitiveness, and potential growth prospects in the global market. Through this meeting, we expect to concretely discuss the direction of business development (BD) and achieve significant results in technology transfer."

STCube plans to expand Nelmastovat’s indications starting with colorectal cancer and small cell lung cancer. In the interim results of the Phase 1b/2 investigator-initiated trial for third-line or later colorectal cancer, the Nelmastovat combination therapy showed an objective response rate (ORR) of 21%, with 4 partial responses (PR) out of 19 MSS (microsatellite stable) colorectal cancer patients. This result is superior to the Keytruda monotherapy (ORR 0%) and Opdivo combination (ORR 7%) clinical trials.

The '43rd JP Morgan Healthcare Conference 2025' will be held from January 13 to 16 in San Francisco, USA. It is a gathering where top decision-makers from global big pharma, pharmaceutical and biotech industry investors, and emerging bio healthcare companies come together to explore business development opportunities.

This content was produced with the assistance of AI translation services.